The FDA approved AstraZeneca’s baxdrostat (Baxfendy), a first-in-class aldosterone synthase inhibitor, for hypertension in combination with other antihypertensive medications for patients whose blood pressure is not adequately controlled. Regulators cleared the drug based on results from the phase 3 BaxHTN study, which met primary and secondary endpoints. AstraZeneca’s approval also sets up a clearer competitive field: Mineralys Therapeutics is preparing a potential next entrant with a December 2026 PDUFA date for lorundrostat. For companies and clinicians, the new mechanism adds a fresh option in a treatment class that had been dominated by existing pathways, and it may accelerate uptake of aldosterone-synthesis targeting strategies where current regimens fall short.